TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP
regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.